The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery
Open accessAbstract
Motivated by the clinical observation that interruption of the mevalonate pathway stimulates immune responses, we hypothesized that this pathway may function as a druggable target for vaccine adjuvant discovery. We found that lipophilic statin drugs and rationally designed bisphosphonates that target three distinct enzymes in the mevalonate pathway have potent adjuvant activities in mice and cynomolgus monkeys. These inhibitors function independently of conventional "danger sensing." Instead, they inhibit the geranylgeranylation of small GTPases, including Rab5 in antigen-presenting cells, resulting in arrested endosomal maturation, prolonged antigen retention, enhanced antigen presentation, and T cell activation. Additionally, inhibiting the mevalonate pathway enhances antigen-specific anti-tumor immunity, inducing both Th1 and cytolytic T cell responses. As demonstrated in multiple mouse cancer models, the mevalonate pathway inhibitors are robust for cancer vaccinations and synergize with anti-PD-1 antibodies. Our research thus defines the mevalonate pathway as a druggable target for vaccine adjuvants and cancer immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Rab GTPases as coordinators of vesicle traffic
Stenmark, H. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2728 · Cited by 3,413
Approaching the Asymptote? Evolution and Revolution in Immunology
Janeway, C. A. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,252
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · cited 1×
“Ideally, an adjuvant should induce a robust response for prophylaxis against infectious diseases such as influenza and would also boost the efficacy of vaccines for non-infectious disease applications, such as cancer (Couzin-Frankel, 2013; Melero et al., 2014; van der Burg et al., 2016).”
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Cross-presentation by dendritic cells
Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012) · Nature Reviews Immunology · doi:10.1038/nri3254 · Cited by 1,637
Pathways of Antigen Processing
Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095910 · Cited by 1,547
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Statins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Youssef, S., Stüve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., et al. (2002) · Nature · doi:10.1038/nature01158 · Cited by 1,097
Lin, K. Y., Guarnieri, F., Staveley-O’Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., & Wu, T. ‐. (1996) · PubMed · Cited by 1,003
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915
Savina, A., Jancic, C., Hugues, S., Guermonprez, P., Vargas, P., Moura, I. C., Lennon-Duménil, A.-M., Seabra, M. C., Raposo, G., & Amigorena, S. (2006) · Cell · doi:10.1016/j.cell.2006.05.035 · Cited by 891
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Differential Lysosomal Proteolysis in Antigen-Presenting Cells Determines Antigen Fate
Delamarre, L., Pack, M., Chang, H., Mellman, I., & Trombetta, E. S. (2005) · Science · doi:10.1126/science.1108003 · Cited by 774
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Statins do more than just lower cholesterol
Vaughan, C. J., Murphy, M. B., & Buckley, B. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05190-2 · Cited by 698
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
Greenwood, J., Steinman, L., & Zamvil, S. S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1839 · Cited by 683
Emerging role of extracellular vesicles in inflammatory diseases
Buzas, E. I., György, B., Nagy, G., Falus, A., & Gay, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.19 · Cited by 677
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
Regulation of microtubule motors by tubulin isotypes and post-translational modifications
Sirajuddin, M., Rice, L. M., & Vale, R. D. (2014) · Nature Cell Biology · doi:10.1038/ncb2920 · Cited by 600
Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS
Park, Y. H., Wood, G., Kastner, D. L., & Chae, J. J. (2016) · Nature Immunology · doi:10.1038/ni.3457 · Cited by 586
Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome
Drenth, J. P. H., Cuisset, L., Grateau, G., Vasseur, C., van de Velde-Visser, S. D., de Jong, J. G. N., Beckmann, J. S., van der Meer, J. W. M., & Delpech & contributing members of t, M. (1999) · Nature Genetics · doi:10.1038/9696 · Cited by 556
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
HEBERT, P. R., GAZIANO, J. M., CHAN, K. S., & HENNEKENS, C. H. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00060 · Cited by 506
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence
Liu, C.-I., Liu, G. Y., Song, Y., Yin, F., Hensler, M. E., Jeng, W.-Y., Nizet, V., Wang, A. H.-J., & Oldfield, E. (2008) · Science · doi:10.1126/science.1153018 · Cited by 490
Self-citationThe TLR4 antagonist Eritoran protects mice from lethal influenza infection
Shirey, K. A., Lai, W., Scott, A. J., Lipsky, M., Mistry, P., Pletneva, L. M., Karp, C. L., McAlees, J., Gioannini, T. L., Weiss, J., et al. (2013) · Nature · doi:10.1038/nature12118 · Cited by 423
Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
Falo, L. D., Kovacsovics-Bankowski, M., Thompson, K., & Rock, K. L. (1995) · Nature Medicine · doi:10.1038/nm0795-649 · Cited by 289
Controlling the location and activation of Rab GTPases
Seabra, M. C., & Wasmeier, C. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.06.014 · Cited by 288
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens
Wegmann, F., Gartlan, K. H., Harandi, A. M., Brinckmann, S. A., Coccia, M., Hillson, W. R., Kok, W. L., Cole, S., Ho, L.-P., Lambe, T., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2344 · Cited by 235
Rosalia, R. A., Quakkelaar, E. D., Redeker, A., Khan, S., Camps, M., Drijfhout, J. W., Silva, A. L., Jiskoot, W., van Hall, T., van Veelen, P. A., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201343324 · Cited by 215
Calabro, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., De Gregorio, E., O’Hagan, D. T., Baudner, B., & Seubert, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.007 · Cited by 214
Control of the innate immune response by the mevalonate pathway
Akula, M. K., Shi, M., Jiang, Z., Foster, C. E., Miao, D., Li, A. S., Zhang, X., Gavin, R. M., Forde, S. D., Germain, G., et al. (2016) · Nature Immunology · doi:10.1038/ni.3487 · Cited by 214
Alloatti, A., Kotsias, F., Pauwels, A.-M., Carpier, J.-M., Jouve, M., Timmerman, E., Pace, L., Vargas, P., Maurin, M., Gehrmann, U., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.11.006 · Cited by 189
Zhang, Y., Cao, R., Yin, F., Hudock, M. P., Guo, R.-T., Krysiak, K., Mukherjee, S., Gao, Y.-G., Robinson, H., Song, Y., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja808285e · Cited by 178
Self-citationRational design of small molecules as vaccine adjuvants
Wu, T. Y.-H., Singh, M., Miller, A. T., De Gregorio, E., Doro, F., D’Oro, U., Skibinski, D. A. G., Mbow, M. L., Bufali, S., Herman, A. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009980 · Cited by 176
Tate, M. D., Brooks, A. G., & Reading, P. C. (2008) · Respiratory Research · doi:10.1186/1465-9921-9-57 · Cited by 163
Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates
Gronich, N., & Rennert, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.169 · Cited by 161
Martin, M., Arnold, W. D., Heath, H. T., Urbina, J. A., & Oldfield, E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1404 · Cited by 153
Self-citationRab GTPases as regulators of endocytosis, targets of disease and therapeutic opportunities
Agola, J. O., Jim, P. A., Ward, H., BasuRay, S., & Wandinger‐Ness, A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01724.x · Cited by 143
Yılmaz, A., Reiss, C., Tantawi, O., Weng, A., Stumpf, C., Raaz, D., Ludwig, J., Berger, T. G., Steinkasserer, A., Daniel, W. G., et al. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.10.002 · Cited by 141
Regulation of endocytic traffic by Rho GTPases
Qualmann, B., & MELLOR, H. (2003) · Biochemical Journal · doi:10.1042/bj20030139 · Cited by 135
Song, L., Nakaar, V., Kavita, U., Price, A., Huleatt, J., Tang, J. T., Jacobs, A., Liu, G., Huang, Y., Desai, P., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002257 · Cited by 115
Self-citationGhittoni, R., Napolitani, G., Benati, D., Uliveri, C., Patrussi, L., Pasini, F. L., Lanzavecchia, A., & Baldari, C. T. (2006) · European Journal of Immunology · doi:10.1002/eji.200636567 · Cited by 85
Clinical investigations of Toll-like receptor agonists
Meyer, T., & Stockfleth, E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.1051 · Cited by 82
Gruenbacher, G., Gander, H., Nussbaumer, O., Nußbaumer, W., Rahm, A., & Thurnher, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1968 · Cited by 75
Song, Y., Lin, F., Yin, F., Hensler, M. E., Rodrigues, C., Mukkamala, D., Cao, R., Wang, H., Morita, C. T., González‐Pacanowska, D., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801023u · Cited by 64
Self-citationHong, C., Qiu, X., Li, Y., Huang, Q., Zhong, Z., Zhang, Y., Liu, X., Sun, L., Lv, P., & Gao, X. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000536 · Cited by 51
Self-citationMevalonate kinase deficiency leads to decreased prenylation of Rab GTPases
Jurczyluk, J., Munoz, M. A., Skinner, O. P., Chai, R. C. C., Ali, N., Palendira, U., Quinn, J. M. W., Preston, A. E., Tangye, S. G., Brown, A. J., et al. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.58 · Cited by 46
Strategies for designing synthetic immune agonists
Wu, T. Y.-H. (2016) · Immunology · doi:10.1111/imm.12622 · Cited by 32
El-Refai, S. M., Brown, J. D., Arnold, S. M., Black, E. P., Leggas, M. L., & Talbert, J. (2017) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00010 · Cited by 27
LEE, P., Scumpia, P. O., Byars, J. A., Kelly, K. B., Zhuang, H., Shuster, J. J., Theriaque, D. W., Segal, M. S., Reeves, W. H., & BRANTLY, M. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.12.042 · Cited by 16
Gonçalves, I., Cherfan, P., Söderberg, I., Fredrikson, G. N., & Jonasson, L. (2009) · Autoimmunity · doi:10.1080/08916930802668602 · Cited by 14
Shi, Y., Smith, K. D., & Lutz, C. T. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4305 · Cited by 10
Self-citationSafety and efficacy of statins
Thompson, P. D., & Taylor, B. A. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30718-3 · Cited by 10
Cited by
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 983
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Huang, B., Song, B.-L., & Xu, C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0174-0 · Cited by 921
Lipid metabolism in cancer progression and therapeutic strategies
Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C., Zhao, Y., et al. (2021) · MedComm · doi:10.1002/mco2.27 · Cited by 393
Metadata
- Authors
- Xia, Y., Xie, Y., Yu, Z., Xiao, H., Jiang, G., Zhou, X., Yang, Y., Li, X., Zhao, M., Li, L., Zheng, M., Han, S., Zong, Z., Meng, X., Deng, H., Ye, H., Fa, Y., Wu, H., Oldfield, E., Hu, X., Liu, W., Shi, Y., & Zhang, Y.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 175
- Issue
- 4
- Pages
- 1059-1073.e21
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2892819708
- Cited by
- 257
- References
- 66
- FWCI
- 6.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.